Stimulants may lead to better engagement in buprenorphine treatment at the cost of a modest increase in drug overdose risk in patients with opioid addiction.
An FDA advisory panel voted in favor of using randomized trials of PI3K drugs instead of single-arm studies in blood cancer studies, because of concerns about toxicities in this class of drugs.
All oncologists surveyed indicated that they ask patients with metastatic breast cancer about side effects at every visit, and the vast majority are open to flexible dosing.